High dose rate brachytherapy in combination with external beam radiotherapy in the radical treatment of prostate cancer: initial results of a randomised phase three trial

Radiotherapy and Oncology

Volumn 84, Issue 2, 2007, Pages 114-120

  Hoskin, Peter J ^a   Motohashi, Kate ^a   Bownes, Peter ^a   Bryant, Linda ^a   Ostler, Peter ^a  

^a MOUNT VERNON CANCER CENTRE   (United Kingdom)

Author keywords

Brachytherapy; External beam; High dose rate; Prostate cancer; Radiotherapy

Indexed keywords

ANTIANDROGEN; PROSTATE SPECIFIC ANTIGEN;

ARTICLE; BRACHYTHERAPY; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER STAGING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DOSIMETRY; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; GENERAL ANESTHESIA; GLEASON SCORE; HISTOLOGY; HUMAN; IMPLANT; MAJOR CLINICAL STUDY; MALE; METASTASIS; METHODOLOGY; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; QUALITY OF LIFE; RADIATION DOSE; RADIATION INJURY; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RECTUM INJURY; TRANSURETHRAL RESECTION; TREATMENT DURATION;

AGED; BRACHYTHERAPY; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROSTATIC NEOPLASMS;

EID: 34548047243     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.radonc.2007.04.011     Document Type: Article

References (26)

1. Pollack A., Zagars G.K., Starkschall G., et al. Prostate cancer radiation dose response: results of the M.D. Anderson phase III randomised trial. Int J Radiat Oncol Biol Phys 53 (2002) 1097-1105
2. Zelefsky M.J., Leibel S.A., Gaudin P.B., et al. Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys 41 (1998) 491-500
3. Bolla M., Collette L., Blank L., et al. Long term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 360 (2002) 103-108
4. Denham J.W., Deigler A., Lamb D., et al. Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. Lancet Oncol 6 (2005) 841-850
5. Davis B.J., Pisansky T.M., Wilson T.M., et al. The radial distance of extraprostatic extension of prostate carcinoma: implications for prostate brachytherapy. Cancer 85 (1999) 2630-2637
6. Blasko J.C., Grimm P.D., Sylsvester J.E., and Cavanagh W. The role of external beam radiotherapy with I-125/Pd-103 brachytherapy for prostate carcinoma. Radiother Oncol 57 (2000) 273-278
7. Khaksar S.J., Langley S.E.M., Lovell D., and Laing R.W. Interstitial low dose rate brachytherapy for prostate cancer - a focus on intermediate- and high-risk disease. Clin Oncol 18 (2006) 513-518
8. Morton G.C. The emerging role of high-dose-rate brachytherapy for prostate cancer. Clin Oncol 17 (2005) 219-227
9. Hoskin P.J. High dose rate brachytherapy boost treatment in radical radiotherapy for prostate cancer. Radiother Oncol 57 (2000) 285-288
10. Bentzen S.M., and Ritter M.A. The α/β ratio for prostate cancer: what is it, really. Radiother Oncol 76 (2005) 1-3
11. Jackson A., Murthy V., and Dearnaley D. External beam radiotherapy for prostate cancer. In: Hoskin P. (Ed). Radiotherapy in practice: external beam therapy (2006), Oxford University Press, Oxford 181-212
12. Hoskin P.J., Bownes P.J., Ostler P., Walker K., and Bryant L. High dose rate afterloading brachytherapy for prostate cancer: catheter and gland movement between fractions. Radiother Oncol 68 (2003) 285-288
13. Dische S., Saunders M.I., Williams C., Hopkins A., and Aird E. Precision in reporting the dose given in a course of radiotherapy. Radiother Oncol 29 (1993) 287-293
14. Common terminology criteria for adverse events v3.0 (CTCAE). Available from: http:/ctep.cancer.gov.
15. Kaplan E.L., and Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 53 (1958) 457-481
16. Cella DF. F.A.C.T. Manual v3.0, June 1996.
17. American Society for Therapeutic Radiology and Oncology Consensus Panel. Consensus statement: guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys 37 (1997) 1035-1041
18. Martinez A., Gonzalez J., Spencer W., et al. Conformal high dose rate brachytherapy improves biochemical control and cause specific survival in patients with prostate cancer and poor prognostic factors. J Urol 169 (2003) 974-979
19. Mate T.P., Gottesman J.E., Hatton J., et al. High dose-rate afterloading 192 iridium prostate brachytherapy: a feasibility report. Int J Radiat Oncol Biol Phys 41 (1998) 525-533
20. Galalae R.M., Kovacs G., Schultze J., et al. Long term outcome after elective irradiation of the pelvic lymphatics and local dose escalation using high-dose-rate brachytherapy for locally advanced prostate cancer. Int J Radiat Oncol Biol Phys 52 (2002) 81-90
21. Pellizzon A.C.A., Nadalin W., Salvajoli J.V., et al. Results of high dose rate afterloading brachytherapy boost to conventional external beam radiation therapy for initial and locally advanced prostate cancer. Radiother Oncol 66 (2003) 167-172
22. Chin Y., Bullard J., Bryant L., et al. High dose rate Iridium-192 brachytherapy as a component of radical radiotherapy for the treatment of localised prostate cancer. Clin Oncol 18 (2006) 474-479
23. Kupelian P.A., Buchsbaum J.C., Patel C., Elshaikh M., Reddy C.A., Zippe C., et al. Impact of biochemical failure on overall survival after radiation therapy for localized prostate cancer in the PSA era. Int J Radiat Oncol Biol Phys 52 (2002) 704-711
24. Lukka H., Hayter C., Warde P., et al., Investigators' of OCOG. A randomized trial comparing two fractionation schedules for patients with localized prostate cancer. Int J Radiat Oncol Biol Phys 57 (2003) S126
25. Chiang P.H., Fu M.F., Wang C.J., et al. High dose rate iridium-192 brachytherapy and external beam radiation therapy for prostate cancer with or without androgen ablation. Int J Urol 11 (2004) 152-158
26. Martinez A., Galalae R., Gonzalez J., et al. No apparent benefit at 5 years from a course of neoadjuvant/concurrent androgen deprivation for patients with prostate cancer treated with a high total radiation dose. J Urol 170 (2003) 2296-2301